Hello Community,

I thought it was time to post my portfolio again and what adjustments and plans are still taking place for the year 2025.

My portfolio currently consists of the classic $IWDA (-0,69 %) , $EIMI (-1,68 %) and the $CSNDX (-1,21 %) .

Further additions are $WGLD (+1,39 %) and $BTC (-1,05 %) only.

My remaining satellites are targeted additions in order to expand the focus to Europe and Japan on the one hand and to provide a yield boost in the portfolio on the other.

I currently continue to invest in all ETFs, gold and Bitcoin on a monthly basis.

Upcoming changes:

I will move a portion from the call money account to the $XEON (+0,01 %) into the

It may be planned to make another additional purchase at $NOVO B (-1,52 %) is planned.

expected new additions this year:

$PANW (-1,27 %)

$ISRG (-1,09 %)

$RKLB (-2,58 %)

These are also joining the ranks as targeted satellites and, for me, represent three further interesting, fast-growing and sustainable sectors.

Have a nice weekend :)

LG

Paul

Good evening everyone,

Here are my favorites for the health sector.

Novo Nordisk $NOVO B (-1,52 %)

Stryker $SYK (-0,86 %)

Intuitive Surgical (P/E ratio 70, P/B ratio 19 🤑) $ISRG (-1,09 %)

Astra Zeneca $AZN (+0,22 %)

Zoetis $ZTS (-1,41 %)

Idexx Lab. $IDXX (-1,21 %)

Amgen (profit margin declining) $AMGN (-0,92 %)

I would be interested to know what your favorites are for a long-term investment?

Last week was observation, today I started to pick up a bit of what was on my watchlist 😊

starting with a share for the medical/healthcare sector $ISRG (-1,09 %)

It is now slowly becoming clear who has what it takes to make good profits in the coming years.

Here are my top 30 companies by category, which I am particularly looking at in the current crash.

Some are still overvalued, others are already very attractive at the current price level.

Tier 1 (high corporate quality and strong growth)

Airbnb $ABNB (-1,7 %)

Alphabet $GOOGL (-1,52 %)

Amazon $AMZN (-1,25 %)

ASML $ASML (-1,02 %)

Axon $AXON (-1,09 %)

Cadence $CDNS (-1,34 %)

Constellation Software $CSU (-0,08 %)

Crowdstrike $CRWD (-1,94 %)

Fair Isaac $FICO (-0,37 %)

Hermes $RMS (-1,82 %)

Intuit $INTU (-1,23 %)

Intuitive Surgical $ISRG (-1,09 %)

Mastercard $MA (-0,92 %)

Meta $META (-1,08 %)

Netflix $NFLX (-0,39 %)

Microsoft $MSFT (-0,49 %)

Palantir $PLTR (-2,1 %)

Tesla $TSLA (-1,71 %)

Tier-2 (high business quality and moderate growth)

Booking $BKNG (-1,57 %)

Costco $COST (-0,67 %)

Ferrari $RACE (+1,02 %)

Moody's $MCO (-1,54 %)

MSCI $MSCI (-0,75 %)

Transdigm $TDG (-4,79 %)

Tier-3 (medium / solid corporate quality and strong growth)

Hims & Hers $HIMS (-6,05 %)

Robinhood $HOOD (-2,15 %)

Roblox $RBLX

Shopify $SHOP (-1,65 %)

Spotify $SPOT (-1,23 %)

The Trade Desk $TTD (-1,1 %)

I bought on Friday and am buying again today - even in the course of the next few days and weeks, when we could probably see even lower prices.

Where are you buying?

$DHR (-1,39 %) is now back at the level of 4 years ago and has been moving more or less sideways at this level for around 6 weeks. The development of the last few quarters was not good, but the forecast is positive again. EPS is expected to rise in the higher double-digit percentage range in Q1 and even more strongly in the further course of the year. Out of 18 analysts (yes, I know) there are 13x Buy/Strong Buy and 5x Hold.

Would the share now be a buy for you, or would you rather go for other candidates (which ones?). Of course, in the medical (technology) sector $ISRG (-1,09 %) which have also recently corrected considerably, but are still valued much higher with a notoriously different chart trend. I'm planning to add further here anyway.

https://stockanalysis.com/stocks/dhr/forecast/

"A bit of stagnation - and above all more inflation" is the title of the Bank of America economists' new forecast.

In such a scenario, companies with pricing power are in demand, i.e. those that can pass on rising costs to customers. These are companies that are already making good profits today and not in the too distant future. Their profits will not be greatly affected by higher interest rates. The companies must not be too cyclical; after all, they must also be able to withstand an economic slowdown.

The investment bank Goldman Sachs has compiled a list of 102 stocks that can still hold their own in a stagflation.

Analysts see the greatest price potential in commodity companies such as $MTDR (+2 %)
Matador Resources, $CVE (+0,53 %)
Cenovus Energy, $AA (-1,37 %)
Alcoa and $DVN (+0,06 %)
Devon Energy. The average price target for these stocks is around 40 percent above the current value. They are followed by tech companies such as $AMZN (-1,25 %)
Amazon, $GOOGL (-1,52 %)
Alphabet, $MSFT (-0,49 %)
Microsoft, $META (-1,08 %)
Meta and $ISRG (-1,09 %)
Intuitive Surgical. The professionals put the potential here at at least 30 percent. This is followed by other commodities and media groups such as $SLB (+0,33 %)
Schlumberger, $COP (+0,3 %)
Conocophillips, $RIO (-0,24 %)
Rio Tinto and $OXY (+0,33 %)
Occidental Petroleum with a potential of between 25 and 30 percent.

Also $WMT (-0,55 %)
Walmart is also on the list; analysts see a price potential of 27 percent for the retailer. For the conglomerate $DHR (-1,39 %)
Danaher experts expect 25 percent and the railroad company $CNR (-0,03 %)
Canadian National Railway is also at the top of the list.

Source (excerpt): WELT / Graphic: ChatGPT

Airbnb $ABNB (-1,7 %)

Amazon $AMZN (-1,25 %)

Axon $AXON (-1,09 %)

Cadence $CDNS (-1,34 %)

Constellation Software $CSU (-0,08 %)

Costco $COST (-0,67 %)

Crowdstrike $CRWD (-1,94 %)

Fair Isaac $FICO (-0,37 %)

Ferrari $RACE (+1,02 %)

Hermes $RMS (-1,82 %)

Hims & Hers $HIMS (-6,05 %)

Intuit $INTU (-1,23 %)

Intuitive Surgical $ISRG (-1,09 %)

Mastercard $MA (-0,92 %)

Microsoft $MSFT (-0,49 %)

Moody's $MCO (-0 %)

MSCI $MSCI (-0,75 %)

Palantir $PLTR (-2,1 %)

Robinhood $HOOD (-2,15 %)

Roblox $RBLX

Shopify $SHOP (-1,65 %)

Tesla $TSLA (-1,71 %)

The Trade Desk $TTD (-1,1 %)

Transdigm $TDG (-4,79 %)

Select a maximum of 8-10 positions from this list that have the best risk/reward ratio and are reasonably valued. Then there is a good chance of outperforming the S&P 500.

Your opinion?

Hims & Hers $HIMS (-6,05 %) has recently had a strong run:

Performance YTD: +140%

Performance 1 year: +553%

Currently Hims & Hers $HIMS (-6,05 %) with a price / sales ratio of 10,6x with an expected annual sales growth of >50% for the next 2 years.

Here you can see the ratio for other selected companies with expected double-digit sales growth for the next few years:

Tesla $TSLA (-1,71 %) 11.7x (17% sales CAGR next 2 years)

ServiceNow $NOW : 18,5x (19%)

Shopify $SHOP (-1,65 %): 18,7x (22%)

Robinhood $HOOD (-2,15 %) : 19,6x (16%)

Intuitive Surgical $ISRG (-1,09 %) : 25,4x (15%)

Axon Enterprise $AXON (-1,09 %) : 26,9x (28%)

Duolingo $DUOL : 27,6x (35%)

Crowdstrike $CRWD (-1,94 %) : 29,7x (25%)

Palantir $PLTR (-2,1 %) : 94,7x (29%)

The comparison is, of course, a bit of a stretch, but it is still interesting to see how Hims & Hers $HIMS (-6,05 %) stands relative to other companies.

What do you think?

Since I $ISRG (-1,09 %) unfortunately ran out, I looked around for alternatives and came across the most important supplier. This is the $SUS (+3,26 %) . I find it very interesting for the long-term part of my portfolio. Perhaps someone else has already looked into the company. Intuitive Surgical recently broke the sound barrier. For the first time, the global market leader for robot-assisted surgery is valued at over 200 billion dollars on the stock market. The US medtech giant's flagship product: the Da Vinci surgical systems. Robots have become indispensable in more and more operating theaters. However, Intuitive Surgical is also dependent on suppliers, for example for simulation software. Here, the Americans rely on the expertise of Surgical Science Sweden. The Scandinavians focus on medical simulation training and software solutions. Healthcare professionals can be taught and trained with the products from Surgical Science Sweden. Whether ultrasound, surgical procedures or routine examinations such as bronchoscopies or colonoscopies - the Swedes cover the entire range. In addition to Surgical Science Sweden's largest customer, robotics specialist Intuitive Surgical, its select clientele also includes medtech giants such as Abbott, Stryker, Boston Scientific and Medtronic. It was only in mid-January that the Swedish company intensified its collaboration with Intuitive Surgical with regard to the simulation software used in the Da Vinci systems. Together, they switched to a fully subscription-based revenue model until 2028. Full precision: The robotic arms of the Intuitive Surgical systems have become indispensable in many operating theaters. Surgical Science Sweden supplies the software for training. This increases the need for simulation software, which Surgical Science Sweden can supply. In recent years, the innovative medtech company has also grown through acquisitions. Just before Christmas, the management team led by CEO Tom Englund announced the acquisition of the British company Intelligent Ultrasound, a specialist in ultrasound simulation. The cost: 45.2 million British pounds (equivalent to 54.4 million euros). A clever move that not only expands Surgical Science Sweden's product portfolio, but also gives it direct access to the British market. Headquartered in Gothenburg, the company has already established local presences in the USA, Israel and China in addition to its headquarters in its home country. The decision-makers at Intelligent Ultrasound have approved the transaction, now the shareholders have to give the green light. Profitable growth Surgical Science Sweden has also seen a significant jump in sales and profits during the coronavirus pandemic thanks to the successful integration of SenseGraphics (2019) and Mimic and Simbionix (both 2021). In 2019, the Scandinavian company reported revenue of 101.5 million Swedish kronor (8.89 million euros) and a net profit of 12.6 million kronor (1.10 million euros). In 2023, Surgical Science Sweden earned a net profit of 234 million kronor (20.5 million euros) on sales of just under 883 million kronor (77.4 million euros). 2024 is likely to have been a year of transition, and growth at Surgical Science Sweden should pick up again from 2025. Analysts expect profits to double between 2023 and 2026, which would bring the P/E ratio down to an attractive 25 next year - with sales rising to just under 113 million euros. Growth opportunities in Asia The Asian market in particular offers considerable organic growth potential for Surgical Science Sweden. The company was recently selected by the Ministry of Defense of a Southeast Asian country to supply 30 units of its TraumaVR simulator. This will be used to train the country's military medical personnel. Value: around 4.5 million euros. - Top position in the niche Surgical Science Sweden operates in a fast-growing market with manageable competition. The company is already benefiting from the success of Intuitive Surgical's surgical robots. The company's share is also in bullish shape again on the chart.